Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...

IO Biotech announced promising findings regarding a novel peptide vaccine designed to counter the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors. The ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Among these factors, the transforming growth factor (TGF)-β family is important in both lineage selection and progression of differentiation of most, if not all, cell and tissue types.

A research team from the School of Chinese Medicine in the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has discovered that C-reactive protein (CRP) can exacerbate kidney ...

Transforming Growth Factor Beta (TGF-β) is a key immune-suppressive factor in the tumor microenvironment (TME) of most solid tumors, often limiting the efficacy of various immune-oncology therapies.

Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...

The research team led by Professor Chen Haiyong (middle) discovers a mechanism of C-reactive protein that exacerbates inflammation in diabetic kidney ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both ...